Key Documents

View All Documentation

B7273

Bezafibrate

Name: Bezafibrate
Brand: SIGMA

≥98%, peroxisome proliferator-activated receptor agonist, solid

Synonym(s):

2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₉H₂₀ClNO₄

CAS Number:

41859-67-0

Molecular Weight:

361.82

NACRES:

NA.77

PubChem Substance ID:

24891983

UNSPSC Code:

12352200

EC Number:

255-567-9

MDL number:

MFCD00078970

Assay:

≥98%

Form:

solid

Quality level:

200

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Bezafibrate, ≥98%, solid

Quality Level

200

assay

≥98%

form

solid

solubility

DMF: soluble, deionized water: insoluble, methanol: soluble

originator

Roche

SMILES string

CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O

InChI

1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)

InChI key

IIBYAHWJQTYFKB-UHFFFAOYSA-N

Gene Information

human ... HBA2(3040), PPARA(5465), PPARD(5467), PPARG(5468)
mouse ... Ppara(19013), Ppard(19015), Pparg(19016)

Description

Application

Bezafibrate has been used:

a supplement in the standard diet (SD) for mice to study its effect on diabetes
to evaluate its effect on hepatitis C virus (HCV) assembly and secretion
to evaluate its effect on gonadal steroidogenesis and spermatogenesis of zebrafish and also used as standard for HPLC

Biochem/physiol Actions

Bezafibrate has the ability to repress HCV assembly and secretion. It is used to treat dyslipidemia.

Bezafibrate is a peroxisome proliferator-activated receptor agonist for PPARα, PPARδ, and PPARγ. Lipoprotein lipase (LPL) activator.

The peroxisome proliferator-activated receptor (PPAR) is a member of the steroid nuclear receptor superfamily. Bezafibrate is a peroxisome proliferator-activated receptor agonist for PPARα, PPARδ, and PPARγ. Lipoprotein lipase (LPL) activator.
PPARgamma agonists, including Bezafibrate, have beneficial effects in the suppression of the inflammatory response during RSV infection and therefore might have clinical efficacy in the course of severe RSV-infection.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Bezafibrate

pictograms

GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode.

Jorge Armando Ardila et al.

Talanta, 103, 201-206 (2012-12-04)

The determination of bezafibrate (BZF) using square-wave voltammetry (SWV) and a cathodically pretreated boron-doped diamond electrode is proposed. Cyclic voltammetry results showed one irreversible oxidation peak for BZF at 1.20 V (vs. Ag/AgCl (3.0 mol L(-1) KCl)) in a 0.04

Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.

Alexander Constantinides et al.

European journal of internal medicine, 23(7), 633-638 (2012-08-21)

Plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) levels predict incident cardiovascular disease, impacting Lp-PLA(2) as an emerging therapeutic target. We determined Lp-PLA(2) responses to statin and fibrate administration in type 2 diabetes mellitus, and assessed relationships of changes in Lp-PLA(2) with subclinical

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Akira Honda et al.

Hepatology (Baltimore, Md.), 57(5), 1931-1941 (2012-08-23)

Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator-activated receptors (PPARs). Recently this agent has come to be recognized as a potential anticholestatic medicine for the treatment of primary biliary cirrhosis (PBC)

View All Related Papers

Global Trade Item Number

SKU	GTIN
B7273-1G	04061833441688
B7273-25G	04061832953014
B7273-5G	04061833441695